GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Medacta Group SA (XSWX:MOVE) » Definitions » Debt-to-EBITDA

Medacta Group (XSWX:MOVE) Debt-to-EBITDA : 2.05 (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Medacta Group Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medacta Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF51.9 Mil. Medacta Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF138.6 Mil. Medacta Group's annualized EBITDA for the quarter that ended in Dec. 2023 was CHF93.1 Mil. Medacta Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 2.05.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Medacta Group's Debt-to-EBITDA or its related term are showing as below:

XSWX:MOVE' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.6   Med: 1.6   Max: 3
Current: 1.61

During the past 9 years, the highest Debt-to-EBITDA Ratio of Medacta Group was 3.00. The lowest was 0.60. And the median was 1.60.

XSWX:MOVE's Debt-to-EBITDA is ranked worse than
56.94% of 432 companies
in the Medical Devices & Instruments industry
Industry Median: 1.21 vs XSWX:MOVE: 1.61

Medacta Group Debt-to-EBITDA Historical Data

The historical data trend for Medacta Group's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medacta Group Debt-to-EBITDA Chart

Medacta Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only 3.00 1.88 1.34 1.56 1.64

Medacta Group Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 0.19 1.75 0.25 2.05

Competitive Comparison of Medacta Group's Debt-to-EBITDA

For the Medical Devices subindustry, Medacta Group's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medacta Group's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medacta Group's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Medacta Group's Debt-to-EBITDA falls into.



Medacta Group Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Medacta Group's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(51.901 + 138.58) / 116.193
=1.64

Medacta Group's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(51.901 + 138.58) / 93.116
=2.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Medacta Group  (XSWX:MOVE) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Medacta Group Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Medacta Group's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Medacta Group (XSWX:MOVE) Business Description

Traded in Other Exchanges
Address
Strada Regina 34, Castel San Pietro, Ticino, CHE, 6874
Medacta Group SA is a Switzerland based company involved in developing, manufacturing and distributing orthopaedic and neurosurgical medical devices worldwide. The company offers solutions for Hip, Knee, Shoulder and Spine.